by Kevin Dooley, MD | Mar 27, 2019 | News and Information
Regeneron Pharmaceuticals has confirmed the cancellation of its previously announced Phase 2 clinical trial for inclusion body myositis (IBM). Regeneron had planned to test two therapies in combination to treat this rare muscle disease, which causes gradually... 
by Kevin Dooley, MD | Jan 7, 2019 | News and Information
Washington University School of Medicine in St. Louis, MO, has announced the opening of an IBM Specialty Clinic devoted to inclusion body myositis. The clinic is run by Dr. Conrad “Chris” Weihl, a leading IBM clinician and researcher. Washington University is known... 
by Kevin Dooley, MD | Dec 5, 2018 | News and Information
In sporadic inclusion body myositis (sIBM), which comes first: inflammation or degeneration? Dr. Christopher Lindberg and his team of researchers in Sweden recently attempted to answer this question. Both of these disease processes are present in the muscles in IBM,... 
by Kevin Dooley, MD | Dec 8, 2017 | News and Information
From the soil of Easter Island to the clinics of Paris, the journey of rapamycin to its current position as a potential treatment for sporadic inclusion body myositis is a fascinating story of scientific discovery. A recent clinical trial provided encouraging results,... 